Health

Joseph Stiglitz, Michael Spence and a global team of leading thinkers are calling for new thinking & new rules for the world economy

Increased financialization is driving healthcare costs and must be addressed in our nation’s public policy.

IMPORTANT: Due to growing concerns around the coronavirus, the INET Conference, as well as these workshops will be postponed. Applicants will soon be provided further information.

The COVID-19 pandemic has thrust us into a new reality, and any course we set now will have huge and lasting repercussions on public health and the economy.

The economic and social costs of the global lockdown have been astronomical but as governments look to begin the process of reopening economies it will be critical to develop strategies that balance both the health and economic risks of the pandemic.

Developing countries, many of which appear not to have felt the health effects of COVID to the same extent as Europe and the US, are nonetheless facing severe economic effects as the pandemic pushes the global economy into a recession.

Technology has played a central role in the response to the COVID-19 pandemic. But that has come with increased risks to privacy. How do we balance our needs for safety, convenience and privacy in the wake of this crisis?

Stigmatizing and relegating an activity to the shadows doesn’t improve anyone’s welfare

Greg Mankiw says there should be a market for kidneys, but not for paying drug addicts to get sterilized.

Economic distress in rural areas and opioid exposure in cities are key indicators of overdose deaths

A better set of approaches for the 21st century.

Price gouging in the US pharmaceutical drug industry goes back more than three decades.

New research points to critical role of public funding in drug discoveries and development for the last decade

Private equity firms have become major players in the healthcare industry. How has this happened and what are the results?

This paper considers the relationship between profits realized from higher insulin list prices, pharmaceutical innovation, and the financial structures of the three dominant insulin manufacturing companies, which set list prices.

As Covid-19 spreads globally in the first quarter of 2020, this paper finds that firms’ primary concerns relate to the collapse of demand, increased uncertainty, and disruption in supply chains

How Investor-owned Physician Practices Are Driving up Healthcare Costs

There is not one opioid crisis in America—there are many. And supply-focused measures won’t stop them.

Pharmaceutical pushers like Purdue “couldn’t have done their dirty work” without America’s increasingly unbalanced economy

Cuba’s entirely state-owned biopharmaceutical industry has been remarkably successful, and can serve as a model for other nations

From the Rust Belt to Rural America, Economic and Social Distress Helped Shape the 2016 US Presidential Election Outcome

Once again, an out-of-control industry is threatening public health on a mammoth scale

Greater efficiency, lower costs, and universal coverage make it the sustainable option, say some top economists

As we face a coronavirus-induced health and economic crisis of uncertain duration, policy makers should be particularly concerned about private equity’s heightened use of debt to buy out healthcare providers and take them private, with no regulatory oversight.

A call to action for a world economy in crisis

Contrary to pharmaceutical company claims, revenue from high insulin prices are going to shareholders, not R&D

Evidence shows pharmaceutical companies won’t stop price-gouging and risking American lives for financial gain in this time of crises – unless we force them.

With the COVID-19 death toll rising, we should question the wisdom and morality of an IP system that silently condemns millions of human beings to suffering and death every year.

The scale of firm exposure to the coronavirus is unprecedented by earlier outbreaks, spans all major economies and is pervasive across all industries

Researchers have shown that the financial and economic impacts of denying women abortion care can last years

John Ruskin helps shed light on what it means to have an economy that demands we die for it

The world is on edge at the prospect of a resurgent wave of infections. Models and speculation are rife, but facts remain scarce, which is why the events in Wisconsin on April 7, and their eventual impact, are so important.